Canagliflozin use does not significantly reduce MI risk in diabetics: Study
Australia: The use of SGLT2 inhibitor canagliflozin does not significantly reduce the risk of myocardial infarction (MI) in the population of CANVAS Program and CREDENCE trial, finds a recent study. The study, published in the journal Cardiovascular Research, included patients with type 2 diabetes and history or high risk of cardiovascular disease (CANVAS Program) or type 2 diabetes and chronic kidney disease (CREDENCE).
Gemma A Figtree, University of Sydney, Sydney, Australia, and colleagues aimed to explore the potential impact of sodium glucose co-transporter 2 inhibition (SGLT2i) on the clinical features of patients presenting with myocardial infarction (MI) through a post-hoc analysis of CANVAS Program and CREDENCE trial given the benefit of SGLT2i.
The study included people with type 2 diabetes and history or high risk of cardiovascular disease (CANVAS Program) or type 2 diabetes and chronic kidney disease (CREDENCE). They were randomized to receive Canagliflozin 100 or 300 mg (combined in the analysis) or placebo.
MI events were adjudicated as ST-elevation myocardial infarction (STEMI), non-STEMI as well as type 1 MI or type 2 MI. 421 first MI events in the CANVAS Program and 178 first MI events in the CREDENCE trial were recorded (83 fatal, 128 STEMI, 431 non-STEMI, and 40 unknown).
Key findings of the study include:
- No benefit of canagliflozin compared with placebo on time to first MI event was observed (HR 0.89).
- Canagliflozin was associated with lower risk for non-STEMI (HR 0.78) but suggested a possible increase in STEMI (HR 1.55), with no difference in risk of type 1 or type 2 MI.
- There was no change in fatal MI (HR 1.22).
"Canagliflozin was not associated with a reduction in overall MI in the pooled CANVAS Program and CREDENCE trial population," wrote the authors. "The possible differential effect on STEMI and Non-STEMI observed in the CANVAS cohort warrants further investigation."
Reference:
The study titled, "Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial," is published in the journal Cardiovascular Research.
DOI: https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvab128/6214523
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.